Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05879055 Recruiting - Clinical trials for Neuroendocrine Neoplasm

A Study of PM8002 Injection in Combination With Chemotherapy in Patients With NEN

Start date: May 17, 2023
Phase: Phase 2
Study type: Interventional

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).

NCT ID: NCT05878405 Recruiting - Clinical trials for Malignant Solid Neoplasm

Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer

Start date: May 30, 2023
Phase: Phase 3
Study type: Interventional

This phase III trial compares the effect of methylene blue mouthwash to standard of care mouthwash for the treatment of oral mucositis pain in patients with cancer. Using methlylene blue mouthwash may improve oral pain in patients with oral mucositis related to cancer and/or cancer treatments compared to usual standard of care.

NCT ID: NCT05878288 Recruiting - Neoplasms Clinical Trials

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

DISCERN
Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.

NCT ID: NCT05877924 Recruiting - Clinical trials for Advanced Malignant Tumors

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Start date: August 15, 2023
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.

NCT ID: NCT05877664 Recruiting - Clinical trials for Advanced Solid Tumor

Study of ZG0895.HCl in Patients With Advanced Solid Tumors

Start date: August 8, 2023
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the tolerability and safety of ZG0895.HCl, and to assess the maximum tolerated dose (MTD)/ recommended phase 2 dose (RP2D) of ZG0895.HCl.

NCT ID: NCT05877651 Completed - Solid Tumors Clinical Trials

MASCT-I in Patients With Metastatic or Recurrent Solid Tumors Who Failed Standard Therapy.

Start date: April 21, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of MASCT-I in patients with metastatic or recurrent solid tumors who failed standard therapy.

NCT ID: NCT05877430 Recruiting - Melanoma Clinical Trials

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Start date: September 11, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.

NCT ID: NCT05875870 Recruiting - Clinical trials for Esophageal Neoplasms

Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer

Start date: July 24, 2023
Phase: N/A
Study type: Interventional

This study plans to investigate the effectiveness of six-week light exposure combined with an exercise training program on improving sleep-wake rhythm, physical and mental symptoms, quality of life, one-year recurrence rate, and one-year survival rate of patients with lung and esophageal cancer.

NCT ID: NCT05875805 Not yet recruiting - Clinical trials for Acute Myeloid Leukemia

A Telehealth Advance Care Planning Intervention

TeleSICP
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.

NCT ID: NCT05875168 Recruiting - Clinical trials for Advanced Solid Tumor

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Start date: August 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.